Skip to main content
Premium Trial:

Request an Annual Quote

Orchid s Revenues Gain 5.3 Percent in Q2 as Loss Narrows

NEW YORK, July 28 (GenomeWeb News) - Orchid Cellmark today reported increased revenues and narrowed losses for the second quarter of 2005.


The company had $15.8 million in revenues, up 5.3 percent from $15 million for the second quarter of 2004.


Research and development costs stayed flat, at $417,000, compared to $454,000 during last year's second quarter.


Orchid's net loss totaled $1.8 million, or $.07 per share, down from $2.1 million, or $.10 per share, for the year-ago period.


As of June 30, Orchid had $12.7 million in cash and cash equivalents, and $14.7 million in short-term investments.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.